Center for Immunity and Immunotherapies

Our Vision

CIIT researchers study rare and common disorders that yield powerful insights into the immune system. We use these insights to pursue innovative therapies for pediatric diseases and conditions.

Harnessing the Power of the Immune System

  • Developing Novel Gene Therapies

    We are pioneering techniques that replace or repair the genes behind severe combined immunodeficiency and other immune disorders.

  • Pinpointing Immune Pathways

    Dr. Richard James' team is gaining ground in its quest to understand drug resistance in patients with B-cell lymphoma.

  • Rapidly Identifying Immune Diseases

    Our experts developed unique approaches to rapidly identify immune diseases. We provide testing services for patients worldwide.

  • We Need Your Help

    Private donors can help us create a brighter future for children with immune disorders.


Engineering and Flow-Cytometric Analysis of Chimeric LAGLIDADG Homing Endonucleases from Homologous I-OnuI-Family Enzymes. Baxter SK, Scharenberg AM, Lambert AR. Methods Mol Biol. 2014;1123:191-221. doi: 10.1007/978-1-62703-968-0_14.

The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Lebrec H, Molinier B, Boverhof D, Collinge M, Freebern W, Henson K, Mytych DT, Ochs HD, Wange R, Yang Y, Zhou L, Arrington J, Christin-Piché MS, Shenton J. Regul Toxicol Pharmacol. 2014 Feb 22. pii: S0273-2300 (14)00032-4. doi: 10.1016/j.yrtph.2014.02.008.

Suppressor of cytokine signaling 3 expression is diminished in sinonasal tissues from patients with chronic rhinosinusitis with nasal polyps. Hulse KE, Chaung K, Seshadri S, Suh L, Norton JE, Carter RG, Kern RC, Conley DB, Chandra RK, Tan BK, Peters AT, Grammer LC 3rd, Harris KE, Torgerson TR, Kato A, Schleimer RP. J Allergy Clin Immunol. 2014 Jan;133 (1):275-7.e1. doi: 10.1016/j.jaci.2013.08.015.

A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-Yadlin A, Buckner JH, Rawlings DJ. J Clin Invest. 2013 May 1;123 (5):2024-36. doi: 10.1172/JCI66963.

See more publications from the Center for Immunity and Immunotherapies

Latest News

  • Seattle Children’s Researchers Pioneer Gene Editing that Kills, Resists HIV
    9.30.15 – Seattle Children’s On the Pulse
    Drs. David Rawlings and Andrew Scharenberg found that gene editing could be used to engineer T cells that resist HIV infection and kill HIV-infected T cells or B-cell tumors. The discovery could help scientists working toward cures for HIV, cancer and other diseases.
  • Seattle Children’s Researchers Team Up with Bluebird Bio on Genome Editing and Gene Therapy Research
    9.10.15 – Press Release
    A collaboration with bluebird bio Inc., a biotechnology company, will help Seattle Children’s Research Institute pursue potentially transformative gene therapies for genetic and rare diseases. Gene therapy research aims to cure pediatric diseases by repairing genes that cause them.
  • Seattle Children’s Research Institute and Kineta launch the Alliance for Children’s Therapeutics
    6.11.14 – Press Release
    Seattle Children’s Research Institute and Kineta Inc. launched the Alliance for Children’s Therapeutics, a first-of-its-kind collaboration created to speed development of medications for children with lupus nephritis, and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.
  • Saving lives with SCID screenings
    1.15.14 – Seattle Children’s On the Pulse
    On Jan. 1, years of work by Seattle Children’s research and clinical staff came to fruition when a test for severe combined immunodeficiency (SCID) was added to Washington’s newborn screening panel for all babies born in our state.

Read more news about the Center for Immunity and Immunotherapies